Shionogi B.V.

4 trials 3 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

0 Completed trials

13 Countries active

3 Unique IMPs

N/A Results reported

Phase II

Top indications

Ischaemic stroke 1 Respiratory syncytial virus infection 1

Top IMPs

CEFIDEROCOL 1 REDASEMTIDE 1 S-606001 1

All trials

4 total

A pharmacokinetics and safety study of cefiderocol in hospitalized pediatric patients from birth to less than 3 months of age with suspected… Not authorised

2023-503757-35-00 Phase II 3 countries CEFIDEROCOL
A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke Recruiting

2022-501890-38-00 Phase II 9 countries REDASEMTIDE
Phase 2b study of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus (RSV) who are at high risk of progression… Recruiting

2025-523156-31-00 Phase II 2 countries
A phase 2, randomized, double-blind study of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease. Recruiting

2025-522146-40-00 Phase II 7 countries S-606001

Showing 1–4 of 4 trials

← All sponsors A–Z